LNCR
MCID: LNG032
MIFTS: 95

Lung Cancer (LNCR) malady

Categories: Genetic diseases, Cancer diseases, Respiratory diseases

Aliases & Classifications for Lung Cancer

Aliases & Descriptions for Lung Cancer:

Name: Lung Cancer 54 12 24 25 66 41 3 14
Non-Small Cell Lung Carcinoma 38 12 14 69
Lung Carcinoma 12 24 52 14
Malignant Neoplasm of Lung 25 29 69
Nsclc 12 52 14
Adenocarcinoma of Lung, Response to Tyrosine Kinase Inhibitor in 54 13
Nonsmall Cell Lung Cancer, Somatic 54 13
Lung Cancer, Protection Against 54 29
Adenocarcinoma of Lung, Somatic 54 24
Non-Small Cell Lung Cancer 12 29
Nonsmall Cell Lung Cancer 54 66
Alveolar Cell Carcinoma 66 29
Lung Cancer, Somatic 54 24
Carcinoma of Lung 12 69
Lung Neoplasms 25 69
Nonsmall Cell Lung Cancer, Response to Tyrosine Kinase Inhibitor in 54
Primary Malignant Neoplasm of Lung 69
Bronchioloalveolar Adenocarcinoma 69
Carcinoma, Non-Small-Cell Lung 42
Carcinoma Non-Small Cell Lung 52
Malignant Tumor of Lung 25
Adenocarcinoma of Lung 66
Lung Malignant Tumors 25
Respiratory Carcinoma 25
Malignant Lung Tumor 25
Pulmonary Carcinoma 25
Pulmonary Neoplasms 25
Cancer of Bronchus 25
Cancer of the Lung 25
Lung Malignancies 25
Pulmonary Cancer 25
Cancer of Lung 12
Lung Neoplasm 12
Cancer Lung 52
Lncr 66

Characteristics:

HPO:

32
lung cancer:
Inheritance autosomal recessive inheritance


Classifications:



Summaries for Lung Cancer

MedlinePlus : 41 lung cancer is one of the most common cancers in the world. it is a leading cause of cancer death in men and women in the united states. cigarette smoking causes most lung cancers. the more cigarettes you smoke per day and the earlier you started smoking, the greater your risk of lung cancer. high levels of pollution, radiation and asbestos exposure may also increase risk. common symptoms of lung cancer include a cough that doesn't go away and gets worse over time constant chest pain coughing up blood shortness of breath, wheezing, or hoarseness repeated problems with pneumonia or bronchitis swelling of the neck and face loss of appetite or weight loss fatigue doctors diagnose lung cancer using a physical exam, imaging, and lab tests. treatment depends on the type, stage, and how advanced it is. treatments include surgery, chemotherapy, radiation therapy, and targeted therapy. targeted therapy uses substances that attack cancer cells without harming normal cells. nih: national cancer institute

MalaCards based summary : Lung Cancer, also known as non-small cell lung carcinoma, is related to interstitial lung disease and colorectal cancer, and has symptoms including alveolar cell carcinoma, coughing and dyspnea. An important gene associated with Lung Cancer is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways/superpathways are Non-small cell lung cancer and Innate Immune System. The drugs Abraxane and Alimta have been mentioned in the context of this disorder. Affiliated tissues include lung, endothelial and bone, and related phenotypes are Decreased viability and cellular

Disease Ontology : 12 A respiratory system cancer that is located in the lung.

Genetics Home Reference : 25 Lung cancer is a disease in which certain cells in the lungs become abnormal and multiply uncontrollably to form a tumor. Lung cancer may or may not cause signs or symptoms in its early stages. Some people with lung cancer have chest pain, frequent coughing, breathing problems, trouble swallowing or speaking, blood in the mucus, loss of appetite and weight loss, fatigue, or swelling in the face or neck. Lung cancer occurs most often in adults in their sixties or seventies. Most people who develop lung cancer have a history of long-term tobacco smoking; however, the condition can occur in people who have never smoked.

OMIM : 54 Lung cancer is the leading cause of cancer deaths in the U.S. and worldwide. The 2 major forms of lung cancer are... (211980) more...

CDC : 3 Lung cancer is the leading cause of cancer death and the second most common cancer among both men and women in the United States.

UniProtKB/Swiss-Prot : 66 Lung cancer: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.

Wikipedia : 71 Lung cancer, also known as lung carcinoma, is a malignant lung tumor characterized by uncontrolled cell... more...

Related Diseases for Lung Cancer

Diseases in the Lung Cancer family:

Lung Benign Neoplasm Lung Carcinoma in Situ
Lung Cancer, Egfr-Related Lung Cancer, Gstm1-Related

Diseases related to Lung Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 510)
id Related Disease Score Top Affiliating Genes
1 interstitial lung disease 31.1 EGFR PTEN TP53
2 colorectal cancer 31.1 BRAF CASP8 EGFR ERBB2 FASLG GSTM1
3 myxedema 30.4 EGFR KRAS PIK3CA PTEN TP53
4 testicular cancer 30.1 BRAF EGFR ERBB2 KRAS TP53
5 estrogen-receptor positive breast cancer 30.0 EGFR ERBB2 TP53
6 multinodular goiter 29.9 EGFR ERBB2 KRAS
7 lung cancer susceptibility 3 12.1
8 lung cancer susceptibility 5 12.0
9 lung cancer susceptibility 4 11.8
10 lung cancer susceptibility 2 11.8
11 hilar lung neoplasm 11.8
12 lung cancer, gstm1-related 11.8
13 lung cancer, egfr-related 11.8
14 small cell lung cancer, childhood 11.7
15 small cell lung cancer, adult 11.7
16 non-small cell lung cancer, childhood 11.7
17 lung squamous cell carcinoma 11.5
18 lambert-eaton myasthenic syndrome 11.3
19 paraneoplastic cerebellar degeneration 11.1
20 asbestosis 11.0
21 lung disease 11.0
22 small cell cancer of the lung, somatic 11.0
23 small cell carcinoma 11.0
24 sarcoma 11.0
25 pancoast tumor 10.9
26 lung hilum cancer 10.9
27 lung benign neoplasm 10.9
28 nail disorder, nonsyndromic congenital, 3, 10.8 DLEC1 EGFR ERBB2 FASLG GSTM1 KRAS
29 systemic lupus erythematosus with nephritis 2 10.8 CASP8 EGFR ERBB2 GSTM1 KRAS PIK3CA
30 muscular dystrophy-dystroglycanopathy , type b, 2 10.8 BRAF EGFR ERBB2 KRAS PIK3CA PTEN
31 split-hand/foot malformation with long bone deficiency 1 10.8 CASP8 EGFR ERBB2 GSTM1 KRAS PIK3CA
32 placenta praevia 10.8 EGFR ERBB2 GSTM1 KRAS PIK3CA RASSF1
33 ladd syndrome 10.8 EGFR ERBB2 GSTM1 KRAS PIK3CA RASSF1
34 adenosquamous cell lung carcinoma 10.7
35 lung large cell carcinoma 10.7
36 basaloid lung carcinoma 10.7
37 lung mixed small cell and squamous cell carcinoma 10.7
38 basal cell carcinoma 7 10.7 CASP8 EGFR ERBB2 FASLG KRAS PIK3CA
39 lung combined type small cell carcinoma 10.7
40 trachea squamous cell carcinoma 10.7 EGFR ERBB2 KRAS PIK3CA PTEN TP53
41 proctitis 10.7 EGFR ERBB2 KRAS PIK3CA PTEN TP53
42 hypogonadotropic hypogonadism 20 with or without anosmia 10.7 EGFR ERBB2 GSTM1 PIK3CA PTEN TP53
43 rhinosporidiosis 10.7 EGFR ERBB2 KRAS PIK3CA PTEN TP53
44 prostatic adenoma 10.7 EGFR ERBB2 KRAS PTEN TP53
45 dental caries 10.7 EGFR ERBB2 KRAS PIK3CA TP53
46 nasal cavity disease 10.7 EGFR ERBB2 KRAS PIK3CA TP53
47 pulmonary fibrosis and/or bone marrow failure, telomere-related, 1 10.7 EGFR ERBB2 KRAS RASSF1 TP53
48 malignant pleural solitary fibrous tumor 10.7 EGFR ERBB2 KRAS PTEN TP53
49 glucose-6-phosphate translocase deficiency 10.7 EGFR ERBB2 PIK3CA PTEN TP53
50 adrenal cortical carcinoma 10.7 EGFR GSTM1 PIK3CA RASSF1 TP53

Graphical network of the top 20 diseases related to Lung Cancer:



Diseases related to Lung Cancer

Symptoms & Phenotypes for Lung Cancer

Symptoms by clinical synopsis from OMIM:

211980

Clinical features from OMIM:

211980

Human phenotypes related to Lung Cancer:

32
id Description HPO Frequency HPO Source Accession
1 alveolar cell carcinoma 32 HP:0006519

UMLS symptoms related to Lung Cancer:


coughing, dyspnea, fever, hemoptysis, snoring

GenomeRNAi Phenotypes related to Lung Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.42 BRAF EGFR KRAS PIK3CA
2 Decreased viability GR00106-A-0 10.42 KRAS
3 Decreased viability GR00221-A-1 10.42 EGFR KRAS PIK3CA
4 Decreased viability GR00221-A-2 10.42 KRAS PIK3CA MAP3K8
5 Decreased viability GR00221-A-3 10.42 ERBB2 MAP3K8
6 Decreased viability GR00221-A-4 10.42 BRAF EGFR PIK3CA ERBB2 MAP3K8
7 Decreased viability GR00301-A 10.42 BRAF KRAS MAP3K8
8 Decreased viability GR00342-S-1 10.42 MAP3K8
9 Decreased viability GR00342-S-2 10.42 MAP3K8
10 Decreased viability GR00342-S-3 10.42 MAP3K8
11 Decreased viability GR00381-A-1 10.42 BRAF KRAS
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 10.3 ERCC6
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.3 ERCC6
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-150 10.3 MXRA5
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-160 10.3 MXRA5
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-167 10.3 CYP2A6
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-17 10.3 CASP8
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-187 10.3 MXRA5
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-20 10.3 ERCC6
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 10.3 ERCC6
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-209 10.3 ERCC6
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-26 10.3 ERCC6
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-28 10.3 CYP2A6
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 10.3 MXRA5
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-58 10.3 EGFR
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.3 CASP8
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-75 10.3 MXRA5
28 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 10.3 ERCC6
29 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 10.3 CASP8 CYP2A6 EGFR ERCC6 MXRA5
30 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.72 GSTM1 MAP3K8 PTEN EGFR ERBB2
31 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 PRKN PTEN SLC22A18 TP53 CASP8
32 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 FASLG PRKN PTEN SLC22A18 TP53 BRAF
33 Increased cell death HMECs cells GR00103-A-0 9.43 MAP3K8 PIK3CA PTEN TP53 EGFR IRF1

MGI Mouse Phenotypes related to Lung Cancer:

44 (show all 22)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.44 BRAF CASP8 EGFR ERBB2 ERCC6 FASLG
2 cardiovascular system MP:0005385 10.42 MAP3K8 PIK3CA PRKN PTEN RASSF1 TP53
3 homeostasis/metabolism MP:0005376 10.39 BRAF CASP8 EGFR ERBB2 ERCC6 FASLG
4 immune system MP:0005387 10.35 BRAF CASP8 EGFR ERCC6 FASLG IRF1
5 mortality/aging MP:0010768 10.34 IRF1 KRAS MAP3K8 PIK3CA PRKN PTEN
6 endocrine/exocrine gland MP:0005379 10.32 IRF1 KRAS PIK3CA PTEN RASSF1 TP53
7 hematopoietic system MP:0005397 10.3 ERCC6 FASLG IRF1 KRAS MAP3K8 PPP2R1B
8 integument MP:0010771 10.3 BRAF CASP8 EGFR ERBB2 ERCC6 FASLG
9 neoplasm MP:0002006 10.27 ERCC6 FASLG IRF1 KRAS MAP3K8 PIK3CA
10 digestive/alimentary MP:0005381 10.24 EGFR ERBB2 FASLG KRAS MAP3K8 PTEN
11 embryo MP:0005380 10.19 BRAF CASP8 EGFR ERBB2 KRAS PIK3CA
12 muscle MP:0005369 10.18 BRAF CASP8 EGFR ERBB2 ERCC6 KRAS
13 nervous system MP:0003631 10.17 BRAF CASP8 EGFR ERBB2 ERCC6 FASLG
14 liver/biliary system MP:0005370 10.16 BRAF CASP8 EGFR ERCC6 FASLG KRAS
15 normal MP:0002873 10.06 BRAF EGFR ERBB2 FASLG IRF1 KRAS
16 hearing/vestibular/ear MP:0005377 10.04 BRAF EGFR ERCC6 KRAS MAP3K8 TP53
17 renal/urinary system MP:0005367 9.92 BRAF CASP8 EGFR FASLG IRF1 KRAS
18 reproductive system MP:0005389 9.91 BRAF DLEC1 EGFR ERBB2 FASLG KRAS
19 respiratory system MP:0005388 9.81 PRKN PTEN TP53 ERBB2 FASLG KRAS
20 pigmentation MP:0001186 9.77 BRAF EGFR KRAS PTEN TP53
21 skeleton MP:0005390 9.7 BRAF EGFR ERBB2 ERCC6 FASLG IRF1
22 vision/eye MP:0005391 9.23 EGFR ERCC6 FASLG KRAS PIK3CA PTEN

Drugs & Therapeutics for Lung Cancer

FDA approved drugs:

(show all 23)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Abraxane 17 46 PACLITAXEL Celgene Approved October 2012
2
Alimta 17 46 PEMETREXED (also Pemetrexed Disodium) Eli Lilly Approved February 2004
3
Avastin 17 46 BEVACIZUMAB Genentech Approved July 2009
4
Cyramza 17 46 RAMUCIRUMAB Eli Lilly Approved April 2014
5
Gemzar 17 46 GEMCITABINE HYDROCHLORIDE Eli Lilly Approved May 1996
6
Gilotrif 17 46 AFATINIB DIMALEATE Boehringer Ingelheim Approved July 2013
7
Hycamtin 17 46 TOPOTECAN HYDROCHLORIDE GlaxoSmithKline/ SmithKline Beecham Approved October 2007/Approved May 1996
8
Iressa 17 46 GEFITINIB AstraZeneca Approved May 2003
9
Keytruda 17 46 PEMBROLIZUMAB Merck Approved September 2014
10
Neutroval 17 tbo-filgrastim Teva Pharmaceutical Approved August 2012
11
Opdivo 17 46 NIVOLUMAB Bristol-Myers Squibb Approved March 2015/ Approved December 2014, Approved March 2015
12
Photodynamic Therapy (& Photofrin) 17 PORFIMER SODIUM Sanofi-aventis Approved January, 1996
13
Photofrin 17 PORFIMER SODIUM QLT Approved January 1998
14
Tarceva 17 46 ERLOTINIB HYDROCHLORIDE Genentech, OSI Pharmaceuticals Approved November, 2004
15
Taxol 17 46 PACLITAXEL Bristol-Myers Squibb Approved August 1997
16
Taxotere 17 46 DOCETAXEL Rhone Poulenc Rorer Approved May 1996
17
Xalkori 17 46 CRIZOTINIB Pfizer Approved August of 2011
18
Xgeva 17 46 DENOSUMAB Amgen Approved June 2013/ Approved November 2010
19
Zometa 17 46 ZOLEDRONIC ACID Novartis Approved August 2001/ Approved February 2002
20
Zykadia 17 46 CERITINIB Novartis Approved April 2014
21
Alecensa 17 ALECTINIB HYDROCHLORIDE Roche Approved December 2015
22
Portazza 17 NECITUMUMAB Eli Lilly Approved November 2015
23
Tagrisso 17 OSIMERTINIB MESYLATE AstraZeneca Approved November 2015

Drugs for Lung Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 866)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
2
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
3
Pemetrexed Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 150399-23-8, 137281-23-3 446556 60843
4
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 184475-35-2 123631
5
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1 33419-42-0 36462
6
Amiodarone Approved, Investigational Phase 4,Phase 3 1951-25-3 2157
7
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
8
Epinephrine Approved, Vet_approved Phase 4,Phase 1,Phase 2,Early Phase 1 51-43-4 5816
9
Midazolam Approved, Illicit Phase 4,Phase 1 59467-70-8 4192
10
Remifentanil Approved Phase 4 132875-61-7 60815
11
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 498142 38904
12
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
13
Vinorelbine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 71486-22-1 60780 44424639
14
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
15
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
16
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
17
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
18
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 54-11-5 942 89594
19
Dalteparin Approved Phase 4,Phase 3,Phase 1,Phase 2 9041-08-1
20
Heparin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 9005-49-6 772 46507594
21
Everolimus Approved Phase 4,Phase 1,Phase 2 159351-69-6 6442177
22
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2,Early Phase 1 22916-47-8 4189
23
Sirolimus Approved, Investigational Phase 4,Phase 1,Phase 2 53123-88-9 5284616 6436030 46835353
24
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 137-58-6 3676
25
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 2078-54-8 4943
26
Nedaplatin Approved Phase 4,Phase 3,Phase 2 95734-82-0
27
Amifostine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 20537-88-6 2141
28
Menthol Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 2216-51-5 16666
29
Trioxsalen Approved Phase 4,Phase 2 3902-71-4 5585
30
Irinotecan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 97682-44-5, 100286-90-6 60838
31
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-02-2 5743
32
Crizotinib Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
33
Armodafinil Approved, Investigational Phase 4,Phase 1,Phase 2 112111-43-0
34
Modafinil Approved, Investigational Phase 4,Phase 1,Phase 2 68693-11-8 4236
35
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1 57-27-2 5288826
36
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 437-38-7 3345
37
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263
38
Bupropion Approved Phase 4,Phase 3,Phase 2,Phase 1 34841-39-9, 34911-55-2 444
39
Acetaminophen Approved Phase 4,Phase 1 103-90-2 1983
40
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 2180-92-9, 38396-39-3 2474
41
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
42
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
43
Ketamine Approved, Vet_approved Phase 4,Phase 2 6740-88-1 3821
44
Pembrolizumab Approved Phase 4,Phase 3,Phase 2,Phase 1 1374853-91-4
45
Osimertinib Approved Phase 4,Phase 3,Phase 2,Phase 1 1421373-65-0 71496458
46
Budesonide Approved Phase 4,Phase 2,Phase 3,Phase 1 51333-22-3 63006 5281004
47
Desflurane Approved Phase 4 57041-67-5 42113
48
Nabilone Approved, Investigational Phase 4,Phase 2,Phase 3 51022-71-0 5284592
49
Aprepitant Approved, Investigational Phase 4,Phase 3,Phase 2 170729-80-3 151165 6918365
50
Fosaprepitant Approved Phase 4,Phase 3,Phase 2 172673-20-0 219090

Interventional clinical trials:

(show top 50) (show all 5382)
id Name Status NCT ID Phase
1 Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT02195453 Phase 4
2 PharmacoEconomic Assessment IRESSA® in the Treatment of Non-Small-Cell Lung Cancer (NSCLC) Unknown status NCT00173524 Phase 4
3 Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01211002 Phase 4
4 A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01028729 Phase 4
5 Maintenance Gemcitabine in the Chinese Advanced Lung Cancer Unknown status NCT01336192 Phase 4
6 Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC) Unknown status NCT00813332 Phase 4
7 Positron Emission Tomography (PET)/Computed Tomography (CT) and Roentgen in Lung Cancer: Evaluation of Patients in General Practice Unknown status NCT00675168 Phase 4
8 The Randomized Controlled Clinical Trial of Kushen Injection Unknown status NCT02346318 Phase 4
9 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer Unknown status NCT00724581 Phase 4
10 Safety Evaluation of Dexmedetomidine for EBUS-TBNA Unknown status NCT01381627 Phase 4
11 Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population Completed NCT02000531 Phase 4
12 Chemotherapy for Patients With Non-Small Cell Lung Cancer Completed NCT00380718 Phase 4
13 A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients Completed NCT01020786 Phase 4
14 Non-small Cell Lung Cancer Registry Completed NCT00099541 Phase 4
15 A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01196078 Phase 4
16 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations Completed NCT01287754 Phase 4
17 Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC) Completed NCT00770588 Phase 4
18 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression Completed NCT01230710 Phase 4
19 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4
20 An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Completed NCT00949910 Phase 4
21 Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC) Completed NCT00686322 Phase 4
22 A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES) Completed NCT00388206 Phase 4
23 Pemetrexed Followed by Docetaxel or in Reverse Sequence Completed NCT01442909 Phase 4
24 A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01066884 Phase 4
25 Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC Completed NCT02497118 Phase 4
26 Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates Completed NCT00765687 Phase 4
27 A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer. Completed NCT00451906 Phase 4
28 Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy Completed NCT00115206 Phase 4
29 Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer Completed NCT00883675 Phase 4
30 A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa Completed NCT01000740 Phase 4
31 Modafinil for the Treatment of Fatigue in Lung Cancer V9.0 Completed NCT00829322 Phase 4
32 A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations Completed NCT01609543 Phase 4
33 Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy Completed NCT02972216 Phase 4
34 Iressa Case Control Study in Japan Completed NCT00252759 Phase 4
35 SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients Completed NCT00608868 Phase 4
36 Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose Completed NCT01465243 Phase 4
37 Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab Completed NCT02316327 Phase 4
38 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4
39 Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC Completed NCT01203917 Phase 4
40 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4
41 Coagulation Profile in Patients Undergoing Video Assisted Thorascopic Surgery (VATS) for Lung Cancer Completed NCT01741506 Phase 4
42 "Red Morphine Drops" for Symptomatic Treatment of Dyspnoea in Lung Cancer Completed NCT00338481 Phase 4
43 Fentanyl Matrix in Lung Cancer Pain Completed NCT01060137 Phase 4
44 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4
45 Carotene and Retinol Efficacy Trial Completed NCT00712647 Phase 4
46 Anesthesia in Flexible Bronchoscopy for Lung Cancer Diagnostic Completed NCT00440960 Phase 4
47 Bio-behavioral Lung Cancer Prevention Program Completed NCT00322205 Phase 4
48 Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma Completed NCT02088515 Phase 4
49 PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy Completed NCT02805166 Phase 4
50 Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration for the Diagnosis of Hilar/Mediastinal Lymphadenopathies Completed NCT01658280 Phase 4

Search NIH Clinical Center for Lung Cancer

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: carcinoma, non-small-cell lung

Genetic Tests for Lung Cancer

Genetic tests related to Lung Cancer:

id Genetic test Affiliating Genes
1 Non-Small Cell Lung Cancer 29
2 Lung Cancer 29 24 GSTM1
3 Lung Cancer, Protection Against 29
4 Neoplasm of Lung 29
5 Neoplasm of the Lung 29
6 Alveolar Cell Carcinoma 29
7 Adenocarcinoma of Lung, Somatic 24 PRKN
8 Lung Cancer, Somatic 24 KRAS

Anatomical Context for Lung Cancer

MalaCards organs/tissues related to Lung Cancer:

39
Lung, Endothelial, Bone, Breast, Lymph Node, Testes, Brain

The Foundational Model of Anatomy Ontology organs/tissues related to Lung Cancer:

18
The Lung

Publications for Lung Cancer

Articles related to Lung Cancer:

(show top 50) (show all 13406)
id Title Authors Year
1
MicroRNA-30a-5p suppresses epithelial-mesenchymal transition by targeting profilin-2 in high invasive non-small cell lung cancer cell lines. ( 28405690 )
2017
2
Pretreatment direct bilirubin and total cholesterol are significant predictors of overall survival in advanced non-small-cell lung cancer patients with EGFR mutations. ( 28006834 )
2017
3
CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy. ( 28179355 )
2017
4
Claudin-1 Protein Expression Is a Good Prognostic Factor in Non-Small Cell Lung Cancer, but only in Squamous Cell Carcinoma Cases. ( 27687058 )
2017
5
Association study between genetic variations in Axin2 gene and lung cancer risk in North Indian population: A multiple interaction analysis. ( 28378643 )
2017
6
Does adenomatous polyposis coli gene promoter 1A methylation increase non-small cell lung cancer risk? A meta-analysis. ( 28497891 )
2017
7
MiR-424 Promotes Non-Small Cell Lung Cancer Progression and Metastasis through Regulating the Tumor Suppressor Gene TNFAIP1. ( 28535539 )
2017
8
The pseudogene DUXAP10 promotes an aggressive phenotype through binding with LSD1 and repressing LATS2 and RRAD in non small cell lung cancer. ( 28029651 )
2017
9
Prevalence of NRAS, PTEN and AKT1 gene mutations in the central nervous system metastases of non-small cell lung cancer. ( 28097440 )
2017
10
Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation. ( 28534943 )
2017
11
miR-592 functions as a tumor suppressor in human non-small cell lung cancer by targeting SOX9. ( 28004116 )
2017
12
Effects of FOXJ2 on TGF-I^1-induced epithelial-mesenchymal transition through Notch signaling pathway in non-small lung cancer. ( 27611107 )
2017
13
Epidermal growth factor receptor-mutant lung cancer in Down syndrome: a case presentation and review of the literature. ( 28507273 )
2017
14
Research on the coagulation function changes in non small cell lung cancer patients and analysis of their correlation with metastasis and survival. ( 28534370 )
2017
15
CACNA1B (Cav2.2) Overexpression and Its Association with Clinicopathologic Characteristics and Unfavorable Prognosis in Non-Small Cell Lung Cancer. ( 28127114 )
2017
16
Expression and clinicopathological significance of S100 calcium binding protein A2 in lung cancer patients of Chinese Han ethnicity. ( 27876462 )
2017
17
PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer. ( 28137741 )
2017
18
Fibroblast Growth Factor Receptor 1 (FGFR1), Partly Related to Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) and Microvessel Density, is an Independent Prognostic Factor for Non-Small Cell Lung Cancer. ( 28088809 )
2017
19
Thyroid cancer 1 (C8orf4) shows high expression, no mutation and reduced methylation level in lung cancers, and its expression correlates with I^-catenin and DNMT1 expression and poor prognosis. ( 28430656 )
2017
20
Prolonged air leak following lobectomy can be predicted in lung cancer patients. ( 28091813 )
2017
21
[Association of Indoor Air Pollution, Single Nucleotide Polymorphism of HIF-1I+ Gene with Susceptibility to Lung Cancer in Han Population in Fujian Province]. ( 28302216 )
2017
22
Tissue Factor Pathway Inhibitor-1 Is a Valuable Marker for the Prediction of Deep Venous Thrombosis and Tumor Metastasis in Patients with Lung Cancer. ( 28246607 )
2017
23
Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer. ( 28534251 )
2017
24
CDK20 interacts with KEAP1 to activate NRF2 and promotes radiochemoresistance in lung cancer cells. ( 28534518 )
2017
25
Polymorphism in XRCC1 gene modulates survival and clinical outcomes of advanced North Indian lung cancer patients treated with platinum-based doublet chemotherapy. ( 28332164 )
2017
26
HLA-A24 ligandome analysis of colon and lung cancer cells identifies a novel cancer-testis antigen and a neoantigen that elicits specific and strong CTL responses. ( 28533942 )
2017
27
MicroRNA-181a-5p Impedes IL-17-Induced Nonsmall Cell Lung Cancer Proliferation and Migration through Targeting VCAM-1. ( 28535543 )
2017
28
Cytoplasmic aryl hydrocarbon receptor regulates glycogen synthase kinase 3 beta, accelerates vimentin degradation, and suppresses epithelial-mesenchymal transition in non-small cell lung cancer cells. ( 27752740 )
2017
29
ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes. ( 28009326 )
2017
30
Matrix Metalloproteinase 14 promotes lung cancer by cleavage of Heparin-Binding EGF-like Growth Factor. ( 28013056 )
2017
31
Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells. ( 28332364 )
2017
32
Contribution of Double-strand Break Repair Gene Nijmegen Breakage Syndrome 1 Genotypes, Gender Difference and Smoking Status to Taiwanese Lung Cancer. ( 28476809 )
2017
33
Response of human non-small-cell lung cancer cells to the influence of Wogonin with SGK1 dynamics. ( 28535249 )
2017
34
Increased Expression of Long Non-Coding RNA BCAR4 Is Predictive of Poor Prognosis in Patients with Non-Small Cell Lung Cancer. ( 28077810 )
2017
35
Image Findings of Rare Case of Peritoneal Carcinomatosis from Non Small Cell Lung Cancer and Response to Erlotinib in F-18 FDG Positron Emission Tomography/Computed Tomography. ( 28533646 )
2017
36
Evaluation of ALK gene rearrangement in central nervous system metastases of non-small-cell lung cancer using two-step RT-PCR technique. ( 28534101 )
2017
37
Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy. ( 28533476 )
2017
38
Induction of Cbl-dependent epidermal growth factor receptor degradation in Ling Zhi-8 suppressed lung cancer. ( 28198003 )
2017
39
Elevated Metabolic Activity on (18)F-FDG PET/CT Is Associated with the Expression of EZH2 in Non-small Cell Lung Cancer. ( 28314309 )
2017
40
The relationship between miR-17-5p, miR-92a, and let-7b expression with non-small cell lung cancer targeted drug resistance. ( 28534369 )
2017
41
Study on the molecular mechanism of Rac3 on regulating autophagy in human lung cancer cells. ( 28534368 )
2017
42
miR-134 suppresses the migration and invasion of nona89small cell lung cancer by targeting ITGB1. ( 28075475 )
2017
43
Genetic variant of miR-4293 rs12220909 is associated with susceptibility to non-small cell lung cancer in a Chinese Han population. ( 28410417 )
2017
44
Emodin induces apoptosis of lung cancer cells through ER stress and the TRIB3/NF-I_B pathway. ( 28184934 )
2017
45
WDR79 promotes the proliferation of non-small cell lung cancer cells via USP7-mediated regulation of the Mdm2-p53 pathway. ( 28406480 )
2017
46
Role of uL3 in Multidrug Resistance in p53-Mutated Lung Cancer Cells. ( 28273808 )
2017
47
Using Twitter to Assess the Public Response to the United States Preventive Services Task Force Guidelines on Lung Cancer Screening with Low Dose Chest CT. ( 28091834 )
2017
48
ARRB1 enhances the chemosensitivity of lung cancer through the mediation of DNA damage response. ( 28035404 )
2017
49
Overexpression of FAM83H-AS1 indicates poor patient survival and knockdown impairs cell proliferation and invasion via MET/EGFR signaling in lung cancer. ( 28198463 )
2017
50
Deep sequencing of the TP53 gene reveals a potential risk allele for non-small cell lung cancer and supports the negative prognostic value of TP53 variants. ( 28240049 )
2017